Advanced Filters
noise

Pasadena, California Clinical Trials

A listing of Pasadena, California clinical trials actively recruiting patient volunteers.

Found 530 clinical trials
A Alexey V. Danilov

Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation

This phase I trial tests the safety and side effects of zanubrutinib in combination with odronextamab and how well it works in treating patients with Richter's transformation. Zanubrutinib, a tyrosine kinase inhibitor, blocks a protein called Bruton tyrosine kinase (BTK), which may help keep cancer cells from growing. Odronextamab is …

18 years of age All Phase 1

BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS

The goal of this clinical trial is to test BSB-1001 which is a new type of cellular therapy to treat blood cancers (AML, ALL and MDS). It will evaluate the safety of BSB-1001 and also determine whether it works to prevent relapse of your cancer.

18 - 70 years of age All Phase 1/2
K Krish Patel, MD

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.

18 years of age All Phase 1
H Harry Chung

Open-Label Extension Protocol to SNK01-AD01 Study

Open-Label Extension Protocol to SNK01-AD01 Study

40 - 85 years of age All Phase 2
G Gayane Ovsepyan

CLF065 for Chronic Pouchitis

This clinical trial is to evaluate investigational compound CLF065 as a treatment for adult patients with chronic pouchitis. The goals are to establish the safety, feasibility and efficacy of weekly dosing of long acting CLF065 versus placebo.

18 - 80 years of age All Phase 2
M Mariana C. Stern

CoGENES Randomized Controlled Trial (RCT)

This clinical trial evaluates the effectiveness of trained community engagement specialists for improving communication on colorectal cancer (CRC) prevention and genetic testing among Hispanic/Latino/a/x (H/L) communities. CRC is the second and third leading cause of cancer deaths among United States (US) H/L men and women respectively. Knowledge of inherited germline …

18 years of age All Phase N/A
E Enrique Vargas, MD

Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study

The purpose of this study is to see if a special light treatment, called photobiomodulation, can help people with memory problems such as Mild Cognitive Impairment or Mild Dementia due to Alzheimer's disease. The light is given to the forehead using an FDA-cleared medical device. This device is cleared to …

55 - 89 years of age All Phase N/A

Implementation of Team Clinic for Type 2 Diabetes (TCT2)

The goal of this clinical trial is to learn if shared medical appointment is an acceptable way to deliver care to youth with type 2 diabetes. The main question[s] it aims to answer are: Is shared medical appointments an acceptable care delivery model for this population? Does shared medical appointment …

12 - 18 years of age All Phase N/A
I Ibrahim Aldoss, MD

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

This phase II trial tests the safety, side effects, and effectiveness of asparaginase Erwinia chrysanthemi during induction chemotherapy followed by consolidation chemotherapy in treating high-risk adults with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma. Asparaginase Erwinia chrysanthemi, a type of protein synthesis inhibitor, is a drug that is made …

18 - 54 years of age All Phase 2
S Sophie Lee

A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine

The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).

18 - 55 years of age All Phase 2

Simplify language using AI